The Journal of laryngology and otology · 2026
Prophylactic and therapeutic use of botulinum toxin in post-parotidectomy fistulas and sialocele: a scoping review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alturo Cesar, Sanabria Alvaro
Аннотация
INTRODUCTION: Sialocele and parotid fistula are complications following parotidectomy. Botulinum toxin type A has emerged as a less invasive alternative to prevent or treat them. This scoping review aimed to map the available evidence regarding the preventive and therapeutic use of botulinum toxin type A.
METHODS: Studies involving patients with salivary gland fistulas or sialocele prevented or treated were included. A comprehensive search was conducted in PubMed, Scopus and Google Scholar.
RESULTS: Thirty-five studies, including 681 patients, were analysed. Most were case reports or case series. Among prophylactic studies, the sialocele rate in botulinum toxin type A groups was 3.4 per cent versus 16.4 per cent in controls, without statistical significance. Among patients treated, resolution was achieved in 92 per cent of cases. Methodological limitations included small sample sizes, heterogeneity in protocols and lack of standardised outcome measures.
CONCLUSIONS: Botulinum toxin type A shows a physiological effect on salivary flow reduction; however, available evidence does not yet support definitive conclusions on efficacy.
METHODS: Studies involving patients with salivary gland fistulas or sialocele prevented or treated were included. A comprehensive search was conducted in PubMed, Scopus and Google Scholar.
RESULTS: Thirty-five studies, including 681 patients, were analysed. Most were case reports or case series. Among prophylactic studies, the sialocele rate in botulinum toxin type A groups was 3.4 per cent versus 16.4 per cent in controls, without statistical significance. Among patients treated, resolution was achieved in 92 per cent of cases. Methodological limitations included small sample sizes, heterogeneity in protocols and lack of standardised outcome measures.
CONCLUSIONS: Botulinum toxin type A shows a physiological effect on salivary flow reduction; however, available evidence does not yet support definitive conclusions on efficacy.